Speaking to Fierce at the European Society for Medical Oncology (ESMO) Congress in Berlin at the time, GSK’s Hesham Abdullah, ...
A GSK medicine that was pulled from the market after failing its confirmatory test in multiple myeloma has new data from a Phase 3 study evaluating it as an earlier line of treatment, and the latest ...
A multiple myeloma drug that GSK withdrew from the market last year now has pivotal trial results showing it beat a Johnson & Johnson product that is a standard of care treatment, laying the ...
CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) and GSK plc (LSE/NYSE: GSK), today announced that the pivotal Phase 3 PIVOT-PO trial evaluating tebipenem HBr ...
GSK’s long-acting asthma treatment has been shown to halve the number of attacks in a pair of phase 3 trials, supporting the Big Pharma’s push toward approval despite falling short on some secondary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results